Crizotinib

A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Also Known As:

Networked: 1974 relevant articles (264 outcomes, 305 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shaw, Alice T: 66 articles (07/2022 - 10/2010)
2.	Ou, Sai-Hong Ignatius: 56 articles (03/2022 - 12/2010)
3.	Camidge, D Ross: 54 articles (06/2022 - 10/2010)
4.	Kim, Dong-Wan: 35 articles (12/2021 - 05/2011)
5.	Solomon, Benjamin J: 30 articles (11/2022 - 12/2010)
6.	Wilner, Keith D: 29 articles (01/2021 - 10/2010)
7.	Christensen, James G: 26 articles (01/2020 - 05/2007)
8.	Nakagawa, Kazuhiko: 24 articles (01/2021 - 10/2011)
9.	Ali, Siraj M: 22 articles (11/2020 - 04/2014)
10.	Ahn, Myung-Ju: 21 articles (12/2021 - 05/2012)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/30/2020 - "Co-MET is an open-label, multi-center, single-arm, phase II trial to assess the safety and efficacy of oral crizotinib in patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutation (cohort 1) or a high MET gene copy number of ≥ 7 (cohort 2). " 09/01/2014 - "Preclinical and single-arm phase I studies have shown that patients with ALK-rearranged non-small cell lung cancer (NSCLC) can be successfully treated with crizotinib. " 04/01/2015 - "Crizotinib is a customized and improved therapeutic option for patients with non-small-cell lung cancer that enhances overall survival without increasing toxicity. " 05/01/2023 - "Effective treatment of MET-amplified non-small cell lung cancer patients with crizotinib: a case description." 12/16/2022 - "Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. "
2.	Neoplasms (Cancer) 05/15/2019 - "Crizotinib dramatically reduced the tumor size and resolved the symptoms. " 12/01/2010 - "Thus, in the future, crizotinib is expected to become a highly used therapeutic for the treatment of ALK-rearranged tumors." 01/01/2018 - "Next-generation ALK inhibitors, more potent and brain-penetrable than crizotinib, may be effective in re-inducing remissions when cancers are still addicted to ALK. " 01/01/2016 - "We describe a case of IMT in a 7-year-old girl involving the cornea, conjunctiva, and the anterior orbit treated with crizotinib, resulting in complete tumor remission." 12/01/2007 - "administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. "
3.	Lung Neoplasms (Lung Cancer) 01/01/2019 - "Crizotinib, an ALK/ROS1/MET inhibitor, is highly effective against ROS1-rearranged lung cancer and is used in clinic. " 01/01/2019 - "Crizotinib is highly effective and safe in patients with ROS1-rearranged lung cancer. " 09/01/2014 - "Despite the excellent efficacy of crizotinib in patients with ALK-positive (ALK(+)) lung cancer, resistance mechanisms--such as secondary mutations in the ALK gene, the activation of other oncogenes, and so on--have been identified as conferring resistance to crizotinib. " 11/06/2020 - "Crizotinib is a low molecular weight, orally available TKI that inhibits ROS1, MET and ALK and is considered the gold standard first-line treatment with demonstrated significant activity for lung cancers harbouring ROS1 gene rearrangements. " 12/03/2011 - "This has also paved the way for the integration of molecular analyses into early phase clinical trials, as demonstrated by the clinical development of crizotinib, effective in lung cancer harbouring Alk rearrangements. "
4.	Brain Neoplasms (Brain Tumor) 03/15/2014 - "This principle might be used to enhance therapeutic efficacy of crizotinib against brain metastases in NSCLC patients." 09/01/2016 - "At present, few studies have reported the efficacy of crizotinib in patients with ALK-rearranged NSCLC with brain metastases. " 07/01/2015 - "Second-generation ALK inhibitors are currently being evaluated, with early studies giving impressive results, notably in patients resistant to crizotinib or with brain metastases. " 06/01/2014 - "The method was successfully applied to analyze crizotinib concentrations in plasma samples collected from children enrolled on a phase I pediatric study investigating the use of crizotinib for treatment of pediatric brain tumors." 01/07/2022 - "Next-generation ALK inhibitors likely increase OS (HR 0.71, 95% CI 0.56 to 0.90, 5 RCTs, 1263 participants, moderate-certainty evidence) and slightly increase ORR (RR 1.18, 95% CI 1.10 to 1.25, 5 RCTs, 1229 participants, moderate-certainty evidence) including a response in measurable brain metastases (RR 2.45, 95% CI 1.7 to 3.54, 4 RCTs, 138 participants) when compared to crizotinib. "
5.	Neoplasm Metastasis (Metastasis) 08/20/2016 - "After taking crizotinib for 3 months, the lung lesions were close to complete response (CR), the brain metastasis were partial response (PR), the abdomen metastasis were CR and the symptom of blurred vision relieved. " 02/01/2015 - "Although likely to be exceeding rare, choroidal metastases from ROS1-rearranged NSCLC can be successfully treated with crizotinib similar to choroidal metastases from ALK-rearranged NSCLC can be successfully treated from another case report." 11/01/2023 - "Switching to the MET inhibitor crizotinib improved liver metastases. " 07/31/2023 - "The metastasis extent, crizotinib response, and progression patterns between the groups were compared. " 07/21/2023 - "TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis."

Related Drugs and Biologics

1.	Anaplastic Lymphoma Kinase
2.	alectinib
3.	Tyrosine Kinase Inhibitors
4.	ceritinib
5.	brigatinib
6.	lorlatinib
7.	Platinum
8.	Phosphotransferases (Kinase)
9.	Pemetrexed (MTA)
10.	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Duration of Therapy
5.	Retreatment